Loading...
•
Jun 30
Avadel Q2 2025 Earnings Report
Avadel Pharmaceuticals reported strong second quarter 2025 financial results, driven by significant growth in LUMRYZ net revenue and achieving net income for the first time since LUMRYZ's launch.
Key Takeaways
Avadel Pharmaceuticals delivered a robust performance in the second quarter of 2025, with LUMRYZ net revenue increasing by 64% year-over-year to $68.1 million. The company achieved a net income of $9.7 million and an EPS of $0.10, marking its first profitable quarter since the launch of LUMRYZ. Patient numbers for LUMRYZ also saw substantial growth, reaching 3,100 patients. The company raised its full-year 2025 revenue guidance to $265 - $275 million, reflecting strong commercial execution and market position.
LUMRYZ net revenue reached $68.1 million in Q2 2025, a 64% increase compared to Q2 2024.
Avadel Pharmaceuticals reported a net income of $9.7 million and diluted EPS of $0.10 for Q2 2025, the first profitable quarter since LUMRYZ's launch.
The number of patients on LUMRYZ grew to 3,100 as of June 30, 2025, a 63% increase from the prior year.
The company raised its full-year 2025 revenue guidance to $265 - $275 million, indicating strong confidence in continued growth.
Avadel
Avadel
Avadel Revenue by Segment
Revenue by Segment
LUMRYZ Net Product Revenue
CapyFin.com Forward Guidance
Avadel Pharmaceuticals has raised its full-year 2025 revenue guidance and provided strong guidance for the upcoming quarter, reflecting continued confidence in LUMRYZ's market performance and strategic investments.
Positive Outlook
- Raised 2025 full-year revenue guidance to $265 - $275 million.
- Guidance for Q3 2025 net product revenue is $71 - $75 million.
- Operating expense guidance for Q3 2025 includes additional investments in LUMRYZ for sales force expansion and marketing programs.
- On track to complete enrollment in pivotal Phase 3 REVITALYZ™ study for LUMRYZ in Idiopathic Hypersomnia (IH) by end of 2025.
- Received Orphan Drug Designation from FDA for LUMRYZ for the treatment of Idiopathic Hypersomnia (IH).